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Dendritic cells (DC) are bone marrow-derived professional
antigen-presenting cells (APC) that are required for the initiation
of immune responses. They exhibit a broad heterogeneity in their
anatomical location, migration pathways, phenotype and func-
tional abilities. Langerhans cells (LC) are the DC of the epidermis
characterized by the expression of CD1a, E-cadherin and Birbeck
granules that distinguish them from other DC members (Hart,
1997; Banchereau and Steinman, 1998). Several studies have
focused on the in vitro generation of DC from haematopoietic
progenitors (Caux et al, 1992; Reid et al, 1992; Strunk et al, 1996)
and it has been demonstrated that the culture of CD34+ cells in the
presence of GM-CSF and TNF-α , gives rise to CD1a+/CD14– and
CD1a–/CD14+ cell precursors around 6 days of culture, which
then differentiate into two subsets including LC (CD1a+/ 
E-cadherin+) and non-LC (CD1a+/E-cadherin–), respectively
(Caux et al, 1996). The addition of TGF-β 1 specifically favours
the differentiation of CD1a+ and CD14+ precursors into CD1a+/
E-cadherin+ LC (Strobl et al, 1996; Caux et al, 1999; Jaksits et al,
1999). 
Several studies underline the fact that tumour-soluble factors
inhibit the differentiation and/or maturation of generated DC from
CD34+ cells, interfering at different levels of the differentiation
pathway, depending on both the histological origin of malignant
cells and the cytokine-stimulating cocktail. Indeed, the addition
of supernatants from renal cell carcinoma cell lines to GM-
CSF/TNF-α stimulated CD34+ cells blocks the differentiation of
both CD14+/CD1a– and CD14–/CD1a+ precursors by triggering
them towards macrophages with a strong phagocytic ability
(Menetrier-Caux et al, 1998). Supernatants of breast and colon
adenocarcinoma cell lines have been shown to affect the initial
steps of DC differentiation from CD34+ progenitors under GM-
CSF/TNF-α /IL-4, resulting in the presence of immature mono-
cytic cells (Gabrilovich et al, 1996). Under the same culture
conditions, Shurin et al (2001) also reported that neuroblastoma-
derived factors inhibit DC maturation and function. In a similar
manner, lung carcinoma conditioned medium was shown to inhibit
DC generation and maturation when CD34+ were cultured in GM-
CSF/IL-4 (Katsenelson et al, 2001). 
In all epithelial skin tumours and particularly in melanoma,
alterations in the number and distribution of epidermal LC
have been reported (Stene et al, 1988; Toriyama et al, 1993). In
the epidermis overlaying primary melanoma, LC decline in
number as melanoma progresses, suggesting that agressive
melanoma cells (MC) may affect the generation and/or
functional maturation of LC. Here, we provide morphologic,
phenotypical and functional evidence that MC differing in
their invasive and metastatic properties (Berthier-Vergnes et al,
1993; Zebda et al, 1994a,b; Béchetoille et al, 2000) inhibit the
initial steps of LC differentiation from CD34+ progenitors, but
Human melanoma cells inhibit the earliest
differentiation steps of human Langerhans cell
precursors but failed to affect the functional maturation
of epidermal Langerhans cells 
O Berthier-Vergnes1, M Gaucherand1, J Péguet-Navarro1, J Plouet2, J-F Pageaux3, D Schmitt1 and M-J Staquet1
1INSERM U 346, Hôpital Edouard Herriot, F-69437 Lyon, France; 2UPR CNRS 9062 IPBS, F-31077 Toulouse, France; 3INSERM U352-INSA, F-69621
Villeurbanne, France 
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failed to affect the phenotypic and functional maturation of fresh
epidermal LC. 
MATERIALS AND METHODS 
Antibodies 
The fluorescein isothiocyanate (FITC)-conjugated mouse mAbs
used were specific for CD34 (Pharmingen, San José, CA), CD14,
CD1a (DAKO, Glostrup, Denmark), CD80, CD83 (Immunotech,
Marseille, France), CD86 (Serotec, Oxford, England) and HLA-
DR (Caltag Laboratories, Burlingame, CA). The phycoerythrin
(PE)-labelled mAb anti-CD1a was purchased from Pharmingen.
The unlabelled mAbs included anti-E-cadherin (Takara, Shuzo Co,
Shiga, Japan), anti-CD40, anti-CD54, anti-CD58, anti-Class I and
anti-Birbeck granules associated Langerin (all from Immunotech).
The monoclonal isotype controls were purchased from Sigma
Chemical Co (St Louis, MO). Neutralizing specific rabbit poly-
clonal antibody against VEGF was used at saturating concentra-
tions, as previously described (Guerrin et al, 1995). 
Human melanoma cells 
Two well-characterized human melanoma clones IC8 and TIC3
derived from a single parental cell line were used: only T1C3 cells
promote lung metastases in animals (Berthier-Vergnes et al, 1993)
and penetrate through the dermal–epidermal junction of human
skin reconstructs (Bechetoille et al, 2000). These cells were
cultured as monolayers in McCoy 5A medium (Gibco, Paisley,
Scotland) supplemented with 10% fetal calf serum (FCS) as
described previously (Zebda et al, 1994a). Normal human fibrob-
lasts isolated from abdominal skin were cultured as described by
Trompezinski et al (2000) and used as controls. 
Generation of human Langerhans cells from cord blood
CD34+ progenitors 
DC with the phenotypic and functional characteristics of LC were
generated as previously described (Caux et al, 1999). Briefly,
haematopoietic progenitors were isolated from human umbilical
cord blood using a MACS isolation kit (Miltenyi Biotec GmBh,
Bergisch Gladbach, Germany), which yielded a purity of more
than 90%. CD34+ progenitors were cultured in the presence of
200 U ml–1 recombinant human (rh) GM-CSF (specific activity
1.1 × 107 U mg–1; kindly provided by Novartis Pharma, Rueil-
Malmaison, France), 25 U ml–1 rh TNF-α (specific activity 2 × 107
U mg–1; kindly provided by Dr Ghanem, Institut Bordet,
Bruxelles) and 0.5 ng ml–1 TGF-β 1 (R&D Systems, Abington,
UK) in RPMI 1640 (GIBCO, Grand Island, NY) supplemented
with 10% fetal bovine serum (FBS, Flow Laboratories, Irvine,
UK), 5 × 10–5 M 2 mercaptoethanol, penicillin (100 U ml–1) and
streptomycin (100 µ g ml–1), referred to as complete medium.
Cultured cells were harvested at day 11 and confirmation of
LC phenotype was performed using the specific LC markers: 
E-cadherin, CD1a and Birbeck granules associated Langerin.
At least 60% of E-cadherin+ cells gated on high light scatter 
parameters were obtained in 10 separate experiments. 
Effects of human melanoma cells on the LC generation
from CD34+ progenitors 
MC (2 × 105 cells cm–2) and CD34+ progenitors (4 × 105 cells cm–2)
were seeded in complete medium in the lower and upper chamber
of 0.4-µ m pore size Transwell dishes, respectively (Costar,
Cambridge, MA). MC were introduced either at the beginning of
culture, at the same time as purified CD34+ cells, or on days 4, 5, 6,
7, 8 of culture. Control experiments were performed in the absence
of melanoma cells, or in the presence of normal fibroblasts. In
some experiments, CD34+ cells were co-cultured with MC only
during the first 7 days of culture, and then cultured alone. In 3
experiments, blocking anti-VEGF antibody was added at saturating
concentrations (Guerrin et al, 1995). In all cases, cultured CD34+
cells were collected after 11 days of culture and analysed for
phenotype and function. In some cases, CD34+ cells were seeded in
the lower chamber, whereas MC were plated in the upper chamber. 
Effect of human melanoma cells on the maturation of
fresh epidermal LC 
Fresh human epidermal LC were prepared and purified as previ-
ously described (Péguct-Navarro et al, 1994). Briefly, epidermal
cell suspensions were obtained by trypsinization of human abdom-
inal skin obtained by plastic surgery (0.05% trypsin, Difco
Laboratories, Detroit, MI, 1 h at 37˚C). LC were enriched by
2 successive density gradient centrifugations on Lymphoprep
(Flobio SA, Courbevoie, France). As assessed by immunofluores-
cence staining with anti-CD1a mAb, the resulting population
routinely contained 75–85% LC. LC (1 × 106 cells well–1) were
placed in the inner transwell chamber and MC (2 × 105) in the
lower chamber. After a 48 h coincubation, LC were analysed for
phenotype and function. 
Immunofluorescence staining procedures and flow
cytometry 
CD34+ cells cultured for 11 days with or without MC and fresh
epidermal LC cultured for 2 days with or without MC were
washed in PBS containing 1% FCS, and stained with a panel of
FITC-or PE-labelled mouse mAbs or with appropriate isotypic
controls. When the mAbs used were unlabelled, cells were subse-
quently incubated with FITC-conjugated F(ab’)2 fragments of goat
anti mouse mAb (1:100, Zymed Labs, San Francisco, CA). For
double labelling, cells were stained with FITC-conjugated CD14
mAb followed by PE-conjugated anti-CD1a mAb. The cells were
analysed by using a FACScan (Becton-Dickinson, Mountain View,
CA, USA) and Cell Quest software. The effect of MC was evalu-
ated by the number of positive DC and the MFI, and expressed as
the percentage of decrease according to the following formula: 
% of decrease =
MFI of CD34
+/MC co-culture – MFI of CD34+ cells × 100
MFI of CD34+ cells alone
For each marker, the percentages of decrease of positive cell
number and MFI were determined from 4–6 separate experiments.
Results were expressed as means ± SD. 
Allogeneic mixed T cell proliferative assays 
T cells, obtained from peripheral blood of healthy donors as previ-
ously described (Péguet-Navarro et al, 1994), were seeded at
1 × 105 cells per well into round-bottom 96-well microplates (Nunc,
Roskilde, Denmark), and incubated for 5 days in the presence of
graded numbers of irradiated (30 Gy) CD34+-derived LC or fresh
epidermal LC in 200 µ l of RPMI-1640 medium containing 10%
human AB serum. T cell proliferation was assessed at day 5, afterpulsing with [3H]-methyl-thymidine (1 µ Ci well–1; Amersham, Les
Ulis, France) for the final 18 h of culture. The incorporated radio-
activity was measured by a direct beta-counter (Matrix 96, Packard
Instrument Co, Meriden, CT). Results were expressed as the mean
cpm ± SD of triplicate cultures. 
Cytokine assays 
TGF-β 1, IL-10 and VEGF secretion were measured in cell-free
culture supernatants of MC, CD34+ cells co-cultured with
melanoma cells, and CD34+ cultured alone, using commercially
available ELISA kits (R & D Systems Inc, Minneapolis, USA).
The quantitative determinations of TGF-β 1, IL-10 and VEGF have
detection limits of 7 pg ml–1, 370 pg ml–1 and 5 pg ml–1, respec-
tively. All experiments were performed in duplicate and results
were expressed as the mean of cytokine per milligram of secreted
proteins (ng mg–1 ± SD). 
Statistical analysis 
The significance of the differences among the percentage of
stained cells and their MFI between CD34+ cells cultured with
or without MC was determined by the ANOVA for repeated
measures and contrasts analysis using JMP™ software (SAS
Institute). We also used these procedures for evaluating the differ-
ential effect of invasive and non-invasive MC. 
RESULTS 
Altered morphology of CD34+-derived cells upon 
co-culture with melanoma cells 
The typical morphology of cells generated from CD34+ progenitors
was strikingly altered when they were co-cultured with human
melanoma cells (MC) (Figure 1). CD34+ cells grown in culture
medium supplemented with GM-CSF, TNF-α and TGF-β 1 formed
small non-adherent aggregates surrounded by predominant, scattered
adherent cells displaying a dendritic morphology with long
projections (Figure 1 A, D). In contrast, CD34+cells co-cultured with
MC from the non-metastatic clone IC8 (Figure 1 B, E) or the
metastatic clone T1C3 (Figure 1 C, F) for 7 or 11 days remained
small, round-shaped and organized mainly in small clusters. CD34+
progenitors cultured with metastatic or non-metastatic MC,
displayed features of undifferentiated, non-adherent cells, distinct
from those of macrophages. It should be noted that both melanoma
clones did not significantly affect the number and the viability of
CD34+-derived cells, as assessed by trypan blue exclusion (data not
shown). 
Human melanoma cells disturb the phenotype of
CD34+-derived cells 
CD34+ progenitors cultured in the presence of GM-CSF, TNF-α
and TGF-β 1 for 11 days mainly differentiated into typical
Langerhans cells (LC), as assessed by high levels of expression of
E-cadherin, as previously reported (Caux et al, 1999). They also
expressed high level of DC markers such as CD40, CD80, CD54,
CD58, CD83, CD86, HLA-DR, HLA-class I. Similar phenotypic
profiles were observed when CD34+ cells were cultured in the
presence of normal fibroblasts (data not shown). Co-culturing
CD34+ cells with MC from the two clones dramatically reduced
the percentage of cells positive for CD1a, CD58, CD80, CD83,
CD86 and E-cadherin, as well as their respective surface expres-
sion level (Figure 2). Whereas the number of cells positive for
CD54, CD40, HLA class I and HLA-DR was not significantly
affected by melanoma cells, their respective surface expression
appeared to be strongly down-regulated (Figure 2). 
CD34+ cells co-cultured with MC for 11 days displayed a two-
to three-fold increased expression of the monocyte CD14 marker,
as assessed by the percentage of positive cells (P = 0.003), as well
as their MFI (P = 0.005) compared to CD34+ cells cultured alone
(Figure 3). The generation of CD14+ cells was concomitant with
a decrease in the percentage of CD1a+ cells (P = 0.001) (Figure 3).
No statistical differences were observed when comparing
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Figure 1 Altered morphology of CD34+-derived cells upon co-culture with human melanoma cells. CD34+ cells were cultured for 7 days (A,B,C) and 11 days
(D,E,F) in medium supplemented with GM-CSF, TNF-α and TGF-β 1, either alone (A,D) or in the presence of human melanoma cells from the non-metastatic
clone IC8 (B,E) or the metastatic clone T1C3 (C,F), as described in Materials and Methods. These typical phase contrast micrographs obtained from purified
CD34+ progenitors from a single donor are representative of 10 different experiments (× 100) Melanoma cells induce defective LC precursor differentiation 1947
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the effect of melanoma cells with different invasive properties
(P = 0.347). 
Human melanoma cells affect the differentiation of
CD34+ cells only during their early stage of proliferation 
We then questioned whether the inhibitory effect of MC on the
differentiation of progenitors took place during the expansion or
the maturation phase. To this end, CD34+ cells were co-cultured
with MC either from day 0 to day 7, or from day 8 to day 11 and
compared for their phenotype 11 days after initiation of the
cultures. A double colour fluorescence labelling for CD1a and
CD14 showed that CD34+ cells cultured with MC from day 8 to
day 11 lacked the CD14 antigen, but mainly expressed CD1a,
closely resembling CD34+-derived DC grown in the absence of
MC (Figure 4A). 5 separate experiments confirm that the
expression of CD1a was unmodified (79.4 ± 2.2% with a MFI of
268.9 ± 130 versus 78.9 ± 5% with a MFI of 323.7 ± 158.8). In
contrast, the dominance of the CD1a+ population over the
CD14+ population was not found when precursors were cultured
with MC either from day 0 to day 11 or day 0 to day 7 (Figure
4A). Cells co-cultured from day 0 to day 7 displayed a
decreased expression of CD1a, CD40, CD80, CD83, CD86, 
E-cadherin, CD54, CD58, HLA-DR and HLA class I at day 11,
in a manner similar to that observed in cells co-cultured from
day 0 to day 11 (Figure 2). We then evaluated the differential
effect of MC on the phenotype of cultured CD34+ cells at
different time points of their proliferation phase. CD34+ cells
were grown in GM-CSF, TNF-α and TGF-β 1 for 4, 5, 6 and 7
days prior to co-culturing with MC until day 11. As shown in
Figure 4B, the earlier the co-culture was started, the more the
CD14+ population was enhanced. These observations indicate
that MC are able to divert the differentiation of cultured CD34+
cells towards a dominant CD14+ population only when the prog-
enitors are in an early growth phase. 
CD34+-derived cells generated in the presence of
melanoma cells stimulated T cells less effectively than
control LC 
To determine whether phenotypic changes of LC precursors co-
cultured with MC correlated with altered antigen-presenting
function, CD34+ cells grown with or without MC were analysed
at day 11 for their ability to induce allogeneic T cell prolifera-
tion. As shown in Figure 5A, LC generated in vitro from CD34+
cells induced significant T cell proliferation. This stimulatory
property was not altered when CD34+ progenitors were co-
cultured with MC from day 8 to day 11 (Figure 5C). In contrast,
CD34+ progenitors co-cultured with MC, either from day 0 to
day 11 (Figure 5A), or even from day 0 to day 7 (Figure 5B),
were less potent than control LC in inducing the proliferation of
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Figure 2 Melanoma cells modulate the phenotype of cultured CD34+ cells.
CD34+ cells were grown in medium supplemented with GM-CSF, TNF-α and
TGF-β 1, either alone or in the presence of human melanoma cells from the
non-metastatic clone IC8 (  ) or with the metastatic clone T1C3 (   ). After 11
days of culture, cells were labelled with different mAbs. The effect of
melanoma cells was expressed as the percentage of decrease of both the
number of positive cells and their respective mean fluorescence intensity
(MFI) calculated as indicated in Materials and Methods. Each bar represents
the mean ± SD of 5 separate experiments 
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Figure 3 Melanoma cells lead to an increase in the CD14 population,
conversely correlated with a decrease in the CD1a population. CD34+ cells
were grown in medium supplemented with GM-CSF, TNF-α and TGF-β 1,
either alone (CD34) or in the presence of human melanoma cells from the
IC8 clone (CD34/IC8) or the T1C3 clone (CD34/T1C3). After 11 days of
culture, cells were stained with antibodies to CD14 and CD1a. Each bar
represents the mean fluorescence intensity (MFI) ± SD or the percentage of
positive cells ± SD (%) of 5 separate experiments 1948 O Berthier-Vergnes et al















































Figure 4 Melanoma cells direct the differentiation of CD34+ cells towards a dominant CD14+ population only when progenitors are in an early growth phase. 
(A) CD34+ cells were grown in medium supplemented with GM-CSF, TNF-α and TGF-β 1, either alone (CD34) or in the presence of human melanoma cells
from the IC8 clone (CD34/IC8). Co-cultures were performed either from day 8 to day 11, day 0 to day 7 or day 0 to day 11, and compared for their expression of
CD1a and CD14 11 days after initiation of the cultures. Data are representative of 5 separate experiments. (B) CD34+ cells were grown in medium
supplemented with GM-CSF, TNF-α and TGF-β 1 for 0, 4, 5, 6 and 7 days prior to co-culture with IC8 melanoma cells until day 11. At day 11, the percentage of
CD14+ cells was evaluated by FACS analysis. In this representative experiment, the percentage of CD14+ cells did not exceed 10% when CD34+ cells were
grown alone for 11 days. Results are representative of 3 separate experiments Melanoma cells induce defective LC precursor differentiation 1949
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allogeneic T cells. Thus, in addition to morphological and
phenotypic alterations, CD34+ progenitors co-cultured with MC
stimulated T cells less effectively than LC generated without
MC. 
VEGF, IL-10 and TGF-β 1 are not responsible for the
inhibition of LC generation 
Because VEGF and IL-10 could affect the DC differentiation
and/or LC function (Caux et al, 1994; Péguet-Navarro et al, 1994;
Gabrilovich et al, 1996), we investigated whether MC could
produce these cytokines. When 2 × 105 MC were plated and grown
without CD34+ cells, secreted VEGF was found to be 2.9 ± 0.1 ng
ml–1 72 h–1 for the TIC3 clone and 0.5 ± 0.08 ng ml–1 72 h–1 for the
IC8 clone. A similar difference in VEGF concentration was found
in supernatants collected during the last 72 h of the day 0–day 11
co-cultures of CD34+ cells with MC. Under the same culture
conditions, IL-10 was not detectable (< 3 pg ml–1 72 h–1) in the
whole supernatants, even after a 10-fold concentration. In addi-
tion, these supernatants were assayed for TGF-β 1, known to be
critical for LC generation in vitro. The level of TGF-β 1 found in
supernatants of MC cultured with and without CD34+ cells never
exceeded that measured in fresh culture medium (0.9 ± 0.03 ng
ml–1). These data indicate that the melanoma clones under study
both secrete VEGF, but not IL-10 or TGF-β 1. 
To investigate whether VEGF could be responsible for the effect
of MC on LC generation, CD34+ cells were co-cultured with MC
from both clones from day 0 to day 11 in the presence of a neutral-
izing antibody against VEGF (Guerrin et al, 1995) or a control
non-immune rabbit IgG. CD34+ cells co-cultured with MC, in the
presence or absence of blocking anti-VEGF exhibited a similar
pattern of double colour fluorescence staining for CD1a and
CD14, as those presented on Figure 4 (day 0–day 11). Thus, the
addition of anti-VEGF was not able to abrogate the effect of MC
from both clones on the differentiation of cultured CD34+ cells.
This finding, reproduced in 3 independent experiments, provides
evidence that VEGF secreted by the two melanoma clones is not
responsible for the inhibition of LC generation. 
Melanoma cells failed to affect the phenotypic and
functional maturation of human epidermal LC 
Given the close proximity of epidermal LC to the primary site of
cutaneous melanoma and their critical role in generating immune
response, we then evaluated whether invasive and non-invasive
MC may affect the phenotypic and functional maturation of
human epidermal LC. To this end, freshly isolated LC from
healthy human skin were cultured with or without MC for 2
days. As previously reported (Péguet-Navarro et al, 1995), fresh
epidermal LC become fully mature DC and express high levels of
HLA-DR, CD40, CD54, CD58, CD80, CD83 and CD86 after a
2 day-period of culture. This phenotypic pattern was unchanged
when co-cultured in the presence of MC from both clones or in the
presence of normal fibroblasts (data not shown). Moreover, inva-
sive and non-invasive MC were unable to alter the proliferative
T cell response induced by allogeneic epidermal LC (Figure 5D).
Thus, MC had no effect on the phenotypic and functional matura-
tion of fresh human epidermal LC. 
DISCUSSION 
A number of studies have demonstrated that tumour cells can
inhibit the differentiation of DC from CD34+ progenitors
(Gabrilovich et al, 1996; Menetrier-Caux et al, 1998; Katsenelson
et al, 2001; Shurin et al, 2001). However, the effect of tumour cells
on LC differentiation has never been reported so far. Because of
the importance of the LC depletion phenomena in skin melanoma
(Stene et al, 1988; Toriyama et al, 1993) and the critical role of LC
in generating local immune response, our study was primarily
focused on the effect of human melanoma cells on LC. To generate
human LC, CD34+ cord blood progenitors were cultured in pres-
ence of GM-CSF/TNF-α with the addition of TGF-β 1, in order to
favour the differentiation of these presursors into the particular LC
pathway. Under these culture conditions, a population predomi-
nantly constituted of epidermal LC was derived on day 11, being
characterized by the E-cadherin and CD1a cell surface expression
and a high APC function, in agreement with that reported by Caux
et al (1999). However, co-culturing of CD34+ cells with MC
altered their differentiation pathway, leading to the appearance of
monocytic CD14+ cells. The induction of CD14 antigen expres-
sion can be specifically and unequivocally attributed to MC, since
it was not observed in the presence of fibroblasts. MC induced a
significant increase in the number of CD14+ cells which was
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Figure 5 Melanoma cells decrease the allogeneic T cell proliferation
induced by cultured CD34+ cells, but do not affect the proliferative T cell
response by epidermal LC. CD34+ cells were grown in medium supplemented
with GM-CSF, TNF-α and TGF-β 1, either alone (  ) or in the presence of
human melanoma cells from the clones IC8 (  ) or T1C3 (   ). CD34+
progenitors were co-cultured with melanoma cells from day 0 to day 11 (A),
from day 0 to day 7 (B) or from day 8 to day 11 (C). After 11 days of culture,
cells were used as stimulator cells for allogenic T cells (105 cells well–1).
Freshly purified LC from the same donor (D) were cultured either alone (  ) or
in the presence of human melanoma cells from the clones IC8 (  ) or T1C3
(  ). After 2 days of culture, LC were used as stimulator cells for allogeneic T
cells (105 cells well–1). The proliferation was evaluated by [3H]-thymidine
uptake and results are expressed as the mean cpm ± SD of triplicate cultures.
The background of T cells alone was 110 ± 30 cpm. Results of each panel are
representative of 5 separate experiments 1950 O Berthier-Vergnes et al
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correlated with a decrease in the number of CD1a+/E-cadherin+
cells. Cells expressed a reduced level of MHC class II, MHC class
I, accessory molecules, and stimulated allogeneic T cells less effi-
ciently than control LC. The induction of apoptotic DC by tumour
cell lines has been reported after co-culture of mature CD34+-derived
DC (14 days of culture) with tumour cells for a period of 24 – 48 h
(Esche et al, 1999; Pirtskhalaishvili et al, 2000). We never
observed melanoma-induced apoptosis in CD34+-derived cells
under our culture conditions. This could be explained by the fact
that TGF-β 1 protects cord blood-derived CD34+ cells from apop-
tosis and increase their survival (Riedl et al, 1997). In addition,
CD34+ cells used here were at an earlier stage of differentiation
than those used by Esche et al (1999). 
MC divert the differentiation of cultured CD34+ cells towards a
dominant CD14+ population only during the earliest steps of differ-
entiation (day 0–day 6) which coincides with the proliferative
growth period, as previously reported for adenocarcinoma cell lines
(Gabrilovich et al, 1996). In addition, the differentiation process
leading to the CD14+ phenotype was more efficient when MC were
added to CD34+ cultures on day 0, as compared with day 4, 5, 6 or
7. By contrast, CD34+ cells cultured with GM-CSF/TNF-α /TGF-
β 1 for 7 days before exposure to MC for 4 additional days (day 8 to
day 11), has no effect on LC generation and function. Also, MC
from both clones had no effect on the phenotype and APC function
of freshly isolated epidermal LC, after a 2-day period of culture.
Taken together, these data demonstrate that MC specifically affect
the earliest differentiation stages of LC precursors, but not the latest
stages of in vitro maturation of epidermal LC, from a relatively
immature state (fresh LC) to a fully mature functional state.
Therefore, it is clear that MC are of critical importance in regu-
lating the number of LC in the skin, by blocking LC generation
rather than affecting resident epidermal LC, as it is the case for
sarcoma-produced factors towards murine LC (Ishida et al, 1998). 
We tested whether in our co-culture system, the tumour factors
already identified for their inhibitory effect on DC differentiation,
were effective inhibitors on LC differentiation. VEGF produced by
breast and colon carcinoma cell lines has been the first identified
factor affecting the early stage of CD34+ cell differentiation under
GM-CSF/TNF-α /IL-4 (first 4 days of culture), leading to the
generation of immature monocytes after 12 days of culture
(Gabrilovich et al, 1996). In our co-culture system, VEGF secreted
by MC is not responsible for the inhibition of DC differentiation,
as demonstrated by blocking studies showing that neutralizing
anti-VEGF antibody did not reverse the inhibitory effect. This
finding has also been reported for human renal carcinoma cell
lines (Ménétrier-Caux et al, 1998). Also, we found that the TIC3
clone produced about 5-fold higher VEGF than the IC8 clone,
whereas both clones have quite similar effect on the CD14+ gener-
ation. Furthermore, the tumour-released factors including TGF-β 1,
IL-10, IL-6 and M-CSF, reported to affect DC generation and/or
LC function (Caux et al, 1994; Péguet-Navarro et al, 1994; Enk
et al, 1997; Menetrier-Caux et al, 1998; Steinbrink et al, 1997)
could also be excluded as possible blocking melanoma-derived
factors since the respective transcripts of these genes were never
detected in the melanoma clones under study, cultured either alone
or in the presence of CD34+ cells, as analysed by cDNA array tech-
nology (Bertheir-Vergnes et al, manuscript in preparation). In
support of this data, neither TGF-β 1 nor IL-10 were detected in
media from MC co-cultured with CD34+ using specific ELISA.
Moreover, only the late differentiation stage (from day 6 to day 12
of culture) has been reported to be affected by IL-6 and M-CSF,
which are produced by renal carcinoma cell lines but not by breast
carcinoma cell lines (Menetrier-Caux et al, 1998). 
Recently, Shurin et al (2001) demonstrated that neuroblastoma-
derived gangliosides (GM3 and GD2) inhibit the generation of DC
from CD34+ cells. In the situation where GD2 and GM3 are critical
factors in blocking LC differentiation, it is unlikely that both
melanoma clones would alter LC generation, because of their
distinct ganglioside profiles; IC8 melanoma cells mainly express
GM3, GM2, GD3 and GD2, whereas TIC3 cells only express low
levels of GM3 (Zebda et al, 1994b). Thus, none of the character-
ized tumour-derived factors able to block the DC differentiation
were found to be effective in our co-culture system. A further char-
acterization of the products secreted by MC, responsible for the
blockade of LC generation, are currently under investigation. 
If our data can be extrapolated to what occurs in vivo, we might
speculate that resident epidermal LC, unsensitive to melanoma-
derived factors, can play their role of APC by trafficking from the
epidermis to regional lymph nodes, inducing a specific immune
response. However, it is possible that melanoma-derived factors
may play a role at an early LC differentiation stage, and would pref-
erentially prevent the LC generation from their precursors. Thus,
CD34+ progenitors leaving the blood circulation and entering the
dermis at the tumour site would be unable to generate LC and repop-
ulate the epidermis because of the inhibitory factors secreted by MC
at this site. The observations that dermal LC are not found around
deeply invasive melanomas (Stene et al, 1988), and that tumour-
infiltrating CD1– cells are detected in the dermis deep to melanoma
(Toriyama et al, 1993) reinforce this hypothesis. As a consequence,
the naturally occurring LC turnover would be severely impaired and
would induce a decline in the number of epidermal LC. This hypoth-
esis is supported by immunohistochemical studies demonstrating
a decrease in LC number in the epidermis overlying primary
melanomas (Stene et al, 1988; Toriyama et al, 1993). 
Collectively, our findings clearly demonstrate the differential
sensitivity of epidermal LC and their precursors to MC, and
suggest that MC may prevent LC generation rather than directly
affecting resident epidermal LC in the neighbouring cutaneous
microenvironment. These data give new insights on the role of
melanoma cells in the local depletion of LC in the epidermis over-
lying primary melanoma, resulting in an impaired development of
anti-tumour immunity leading to tumour progression, rather than a
defect in the ability of LC to migrate from the skin to draining
lymph nodes. 
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